“Msd Italia’s commitment is concrete and today it focuses its spotlight on a communication campaign on correct information precisely because even today, unfortunately, in this rare disease too much time still passes before the correct diagnosis arrives and therefore, if it takes too much time before reaching the diagnosis, the disease clearly progresses and it will be more difficult to be effective for the health of the patient himself”. This is what was stated by the president and managing director of MSD Italia, Nicoletta Luppi, on the occasion of the launch of the disease awareness campaign promoted by MSD with the patronage of Amip, Association of Pulmonary Hypertension Patients and Aipi, Italian Pulmonary Hypertension Association, entitled ‘To the Heart of Breath. Pulmonary arterial hypertension, know it in depth’, which aims to increase knowledge and awareness of this serious clinical condition which, if not adequately treated, degenerates, also involving the heart, which is no longer able to pump blood through the lungs.
What are the long-term effects of untreated pulmonary arterial hypertension?
Interview: Understanding Pulmonary Arterial Hypertension and the Importance of Timely Diagnosis
In this exclusive interview, we speak with Nicoletta Luppi, the President and Managing Director of MSD Italia, about the recent awareness campaign on pulmonary arterial hypertension (PAH) and the significance of timely diagnosis in managing this serious condition.
Q: Nicoletta, can you explain what inspired MSD Italia to launch the ‘To the Heart of Breath’ campaign?
A: The inspiration behind the ‘To the Heart of Breath’ campaign stems from our commitment to improve patient outcomes in pulmonary arterial hypertension. Despite being a rare disease, PAH often goes undiagnosed for too long, leading to complications that can severely affect a patient’s health. We want to shine a spotlight on the importance of correct information surrounding this condition, raising awareness among both the public and healthcare professionals to speed up the diagnostic process.
Q: Why is timely diagnosis critical for patients with pulmonary arterial hypertension?
A: Pulmonary arterial hypertension is a progressive condition that, if left untreated, can lead to serious health issues, including heart failure. A timely diagnosis is crucial because the longer it takes to identify PAH, the more the disease can progress, making effective treatment increasingly difficult. Early intervention can significantly enhance a patient’s quality of life and overall health outcomes.
Q: How does MSD Italia plan to increase awareness of this disease through the campaign?
A: Our campaign, supported by the patronage of AMIP and AIPI, includes various initiatives such as educational webinars, distribution of informative materials, and outreach programs targeting both the general public and healthcare providers. By providing comprehensive resources, we aim to empower individuals with knowledge about PAH, its symptoms, and the importance of seeking timely medical attention.
Q: What are some common symptoms of pulmonary arterial hypertension that both patients and doctors should be aware of?
A: Some common symptoms include unexplained shortness of breath, fatigue, chest pain, and swelling in the ankles or legs. Unfortunately, these symptoms can often be overlooked or attributed to other conditions, which contributes to delayed diagnosis. It’s essential for both patients and physicians to maintain a heightened awareness of these symptoms, especially in patients with a history of heart or lung issues.
Q: What practical advice could you offer to patients who suspect they might have PAH?
A: If someone suspects they may have pulmonary arterial hypertension, the first step is to consult a healthcare provider as soon as possible. Being proactive and discussing any symptoms or health concerns with a doctor can lead to earlier testing and diagnosis. It’s also vital to advocate for oneself—if you feel something is wrong, don’t hesitate to seek multiple opinions or further testing.
Q: Looking forward, what do you believe are the key steps needed to improve outcomes for patients with pulmonary arterial hypertension?
A: Improved outcomes in PAH hinge on three critical factors: awareness, education, and research. Raising public and professional awareness of PAH is essential to shorten the diagnostic timeline. Additionally, further education on management strategies and treatment options empowers healthcare providers to make informed decisions. Lastly, continued investment in research will lead to more effective therapies and a better understanding of this complex disease.
Q: How can readers get involved in increasing awareness about pulmonary arterial hypertension?
A: Readers can contribute by sharing information about PAH through social media platforms and engaging with our campaign materials. Additionally, joining support groups or attending awareness events can foster community support for those affected. Every conversation counts, so spreading the word about the symptoms and the significance of timely diagnosis can make a significant difference in many lives.
the ‘To the Heart of Breath’ campaign by MSD Italia plays a pivotal role in transforming the landscape of pulmonary arterial hypertension awareness, encouraging timely diagnosis and effective treatment pathways. By fostering understanding and communication, we can progress towards better health outcomes for patients with this condition.